Walk-run training improves the anti-inflammation properties of high-density lipoprotein in patients with metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 870-879

  Sang, Hui ^a   Yao, Shutong ^a   Zhang, Liying ^a,c   Li, Xiuhong ^b,d   Yang, Nana ^a   Zhao, Jianxiang ^a   Zhao, Li ^a,c   Si, Yanhong ^a   Zhang, Ying ^a   Lv, Xiaohong ^b,d   Xue, Yazhuo ^a   Qin, Shucun ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b TAIAN CENTRAL HOSPITAL   (China)

^c CHENGDE MEDICAL COLLEGE   (China)

^d Central Hospital of Taian   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTIOXIDANT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CASE CONTROL STUDY; CELL ADHESION; CELL DAMAGE; CELL STIMULATION; CELL VIABILITY; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; JAPAN; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MONOCYTE; MTT ASSAY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UMBILICAL VEIN ENDOTHELIAL CELL; WAIST CIRCUMFERENCE; WALK RUN TRAINING; WEIGHT REDUCTION; BLOOD; CELL CULTURE; COMPLICATION; CONTROLLED CLINICAL TRIAL; INFLAMMATION; KINESIOTHERAPY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RUNNING; WALKING;

TAIA;

ADULT; AGED; ANTIOXIDANTS; CASE-CONTROL STUDIES; CELLS, CULTURED; EXERCISE THERAPY; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RUNNING; WALKING;

EID: 84924973464     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2979     Document Type: Article

References (35)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752.
2. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483-1492.
3. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342-374.
4. Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66(6):7A-10A.
5. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol. 2009;24(5):473-482.
6. Ferretti G, Bacchetti T, Nègre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis. 2006;184(1):1-7.
7. Matsunaga T, Iguchi K, Nakajima T, et al. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem Biophys Res Commun. 2001;287(3):714-720.
8. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3(3):144-153.
9. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord. 2009;7(2):83-88.
10. Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol. 2006;101(6):1727-1732.
11. Song G, Li M, Sang H, et al. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J Lipid Res. 2013;54(7):1884-1893.
12. Itahara T, Suehiro T, Ikeda Y, et al. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb. 2000;7(3):152-158.
13. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110-122.
14. Yang N, Qin S, Wang M, et al. Pinocembrin, major flavonoid in propolis, improves the biological functions of EPCs derived from rat bone marrow through the PI3K-eNOS-NO signaling pathway. Cytotechnology. 2013;65(4):541-551.
15. Arikawa AY, Thomas W, Schmitz KH, Kurzer MS. Sixteen weeks of exercise reduces C-reactive protein levels in young women. Med Sci Sports Exerc. 2011;43(6):1002-1009.
16. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):786-798.
17. Pattyn N, Cornelissen VA, Eshghi SR, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 2013;43(2):121-133.
18. Nam JS, Park JS, Cho MH, et al. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Diabetes Res Clin Pract. 2009;84(2):145-151.
19. Scuteri A, Cunha PG, Rosei EA, et al. Arterial stiffness and influences of the metabolic syndrome: A cross-countries study. Atherosclerosis. 2014; 233(2):654-660.
20. Hayashi K, Sugawara J, Komine H, Maeda S, Yokoi T. Effects of aerobic exercise training on the stiffness of central and peripheral arteries in middle-aged sedentary men. Jpn J Physiol. 2005;55(4):235-239.
21. Tölle M, Pawlak A, Schuchardt M, et al. HDL-associated lysosphingolipids inhibit NAD(P) Hoxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol. 2008;28(8):1542-1548.
22. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764-772.
23. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009;58(12):2711-2717.
24. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraox-onase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004;318(3):680-683.
25. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284-287.
26. Tomás M, Elosua R, Sentí M, et al. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J Lipid Res. 2002;43(5):713-720.
27. Liang KW, Lee WJ, Lee IT, et al. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese nondiabetic men with metabolic syndrome. Clin Chim Acta. 2011;412(19-20):1835-1841.
28. Choudhury RP, Leyva F. C-reactive protein, serum amyloid A protein, and coronary events. Circulation. 1999;100(15):e65-6.
29. Lee HY, Kim SD, Shim JW, et al. Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol. 2008;181(6):4332-4339.
30. Badolato R, Wang JM, Murphy WJ, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med. 1994;180(1):203-209.
31. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121(7):2693-708.
32. Besler C, Heinrich K, Riwanto M, Lüscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des. 2010;16(13):1480-1493.
33. Thuahnai ST, Lund-Katz S, Dhanasekaran P, et al. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Biol Chem. 2004;279(13):12448-12455.
34. Khovidhunkit W, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J Lipid Res. 2001;42(6):967-975.
35. Rosenson RS, Brewer HB Jr., Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905-1919.